Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details
Open AccessResearch

Cost estimates of HIV care and treatment with and without anti-retroviral therapy at Arba Minch Hospital in southern Ethiopia

Asfaw Demissie Bikilla1,2* email, Degu Jerene3* email, Bjarne Robberstad1,4* email and Bernt Lindtjorn1* email

Center for International Health, University of Bergen, PO Box 7804, 5020 Bergen, Norway

Faculty of Business and Economics, Hawassa University. PO Box 278, Hawassa, Ethiopia

Arbaminch Hospital, Arba Minch, Ethiopia

Department of Public Health and Primary Health Care, University of Bergen, Bergen, Norway

author email corresponding author email* Contributed equally

Cost Effectiveness and Resource Allocation 2009, 7:6doi:10.1186/1478-7547-7-6

Published: 13 April 2009

Abstract

Background

Little is known about the costs of HIV care in Ethiopia.

Objective

To estimate the average per person year (PPY) cost of care for HIV patients with and without anti-retroviral therapy (ART) in a district hospital.

Methods

Data on costs and utilization of HIV-related services were taken from Arba Minch Hospital (AMH) in southern Ethiopia. Mean annual outpatient and inpatient costs and corresponding 95% confidence intervals (CI) were calculated. We adopted a district hospital perspective and focused on hospital costs.

Findings

PPY average (95% CI) costs under ART were US$235.44 (US$218.11–252.78) and US$29.44 (US$24.30–34.58) for outpatient and inpatient care, respectively. Estimates for the non-ART condition were US$38.12 (US$34.36–41.88) and US$80.88 (US$63.66–98.11) for outpatient and inpatient care, respectively. The major cost driver under the ART scheme was cost of ART drugs, whereas it was inpatient care and treatment in the non-ART scheme.

Conclusion

The cost profile of ART at a district hospital level may be useful in the planning and budgeting of implementing ART programs in Ethiopia. Further studies that focus on patient costs are warranted to capture all patterns of service use and relevant costs. Economic evaluations combining cost estimates with clinical outcomes would be useful for ranking of ART services.


© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.